Ключевые слова
Как цитировать
Аннотация
Активное внедрение скрининговых программ позволяет надеяться на существенное увеличение доли пациентов с ранними формами немелкоклеточного рака лёгкого. Хирургическое лечение, являющееся стандартом лечения локализованных форм заболевания, в связи с функциональными ограничениями может быть выполнено только у 65-70% больных. Очевидно, что решение задачи улучшения результатов лучевой терапии лежит на пути использования современной высокотехнологичной аппаратуры, совершенствования систем планирования, методик подведения доз облучения, режима фракционирования. Стереотаксическая лучевая терапия позволяет в короткие сроки производить высокоточную доставку к опухоли высокой дозы излучения с минимальным повреждением окружающих здоровых тканей. В литературном обзоре, на основе анализа большого числа публикаций, показано, что пока не представляется возможным сделать обоснованные выводы об эффективности и безопасности стереотаксической лучевой терапии в качестве альтернативы хирургическому методу, необходимо безотлагательное проведение рандомизированных контролируемых исследований с учётом предполагаемого высокого потенциала метода.Библиографические ссылки
Борисова Т.Н., Назаренко А.В., Ткачев С.И. и др. Стереотаксическая гипофракционная радиотерапия больных раком лёгкого I-IIA клинической стадии: роль оценки SUVMAX при ПЭТ/КТ с 18F-ФДГ для контроля за результатами лечения // Вопросы онкологии. - 2017. - Т. 63(4). - С. 632-638.
Bertolaccini L., Terzi A., Ricchetti F., Alongi F. Surgery or stereotactic ablative radiation therapy: how will be treated operable patients with early stage not small cell lung cancer in the next future? // Ann. Transl. Med. - 2015. - Vol. 3(2). - P. 25.
Bilal H., Mahmood S., Rajashankerc B., Shaha R. Is radiofrequency ablation more effective than stereotactic ablative radiotherapy in patients with early stage medically inoperable non-small cell lung cancer? // Interactive Cardiovascular and Thoracic Surgeryio - 2012. - Vol. 15. - P. 258-265.
Bollineni V.R., Widder J., Pruim J., Langendijk J.A., Wiegman E.M. Residual 18F-FDG-PET Uptake 12 Weeks After Stereotactic Ablative Radiotherapy for Stage I Non-Small-Cell Lung Cancer Predicts Local Control // Radiation Oncol. Biol. Phys. - 2012. - Vol. 83. - № 4. - P 551555.
Cao С., Gupta S., Chandrakumar D. et al. Meta-analysis of intentional sublobar resections versus lobectomy for early stage non-small cell lung cancer // Ann. Cardiothorac. Surg. - 2014. - Vol. 3(2). - P 134-141.
Chan O.S.H., Lee V.H.F., Mok T.S.K. et al. The role of radiotherapy in epidermal growth factor receptor mutation-positive patients with oligoprogression: a matchedcohort analysis // Clin. Oncol. - 2017. - Vol. 29. - P 568-575.
Chang J.Y, Senan S., Paul M.A. et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I nonsmall-cell lung cancer: a pooled analysis of two randomised trials // Lancet Oncol. - 2015. - Vol. 16. - № 6. - P. 630-637.
Dziedzic R., Zurek W., Marjanski T. et al. Stage I nonsmall-cell lung cancer: long-term results of lobectomy versus sublobar resection from the Polish National Lung Cancer Registry // Eur. J. Cardiothorac. Surg. - 2017. - Vol. 52(2). - P. 363-369.
Gan G., Weickhardt A.J., Scheier B. et al. Stereotactic Radiotherapy Can Safely and Durably Control Sites of Extra-CNS Oligoprogressive Disease in ALK-Positive Lung Cancer Patients on Crizotinib // Int. J. Radiat. Oncol. Biol. Phys. - 2014. - Vol. 88(4). - P 892-898.
Grills I.S., Mangona V.S., Welsh R. et al. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer // J. Clin. Oncol. - 2010. - Vol. 28. -№ 6. - P 928-935.
Grills I.S., Hope A.J., Guckenberger M. et al. A Collaborative Analysis of Stereotactic Lung Radiotherapy Outcomes for Early-Stage Non-Small-Cell Lung Cancer Using Daily Online Cone-Beam Computed Tomography Image-Guided Radiotherapy // J. Thorac. Oncol. - 2012. - Vol. 7. - P. 1382-1393.
Haasbeek C.J., Lagerwaard F.J., Slotman B.J., Senan S. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer // J. Thorac. Oncol. - 2011. - Vol. 6. - P. 2036-2043.
Kestin L., Grills I., Guckenberger M. et al. Dose-response relationship with clinical outcome for lung stereotactic body radiotherapy (СТЛТ) delivered via online image guidance // Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology. - 2014. - Vol. 110. - P. 499- 504.
Lee S., Song S.Y, Kim S.S. et al. Feasible Optimization of Stereotactic Ablative Radiotherapy Dose by Tumor Size for Stage I Non- Small Cell Lung Cancer // Clinical Lung Cancer. - 2017. - DOI: 10.1016/j.cllc.2017.11.001
Ma L. and Xiang J. Clinical outcomes of video-assisted thoracic surgery and stereotactic body radiation therapy for early-stage non-small cell lung cancer: A meta-analysis // Thorac. Cancer. - 2016. - Vol. 7(4). - P. 442-451.
Mahmood S., Bilal H., Faivre-Finn C., Shahb R. Is stereotactic ablative radiotherapy equivalent to sublobar resection in high-risk surgical patients with Stage I nonsmall-cell lung cancer? // Interact. Cardiovasc. Thorac. Surg. - 2013. - Vol. 17(5). - P 845-853.
McDonald F., Hanna G.G. Oligoprogressive Oncogene-addicted Lung Tumours: Does Stereotactic Body Radiotherapy Have a Role? Introducing the HALT Trial // Clinical Oncology. - 2017. - DOI: 10.1016/j.clon.2017.10.013
Onishi H., Shirato H., Nagata Y Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study // J. Thorac. Oncol. - 2007. - Vol. 2. - P 94-100.
Palma D., Visser O., Lagerwaard F.J. et al. Impact of Introducing Stereotactic Lung Radiotherapy for Elderly Patients With Stage I Non-Small-Cell Lung Cancer: A Population-Based Time-Trend Analysis // J Clin Oncol. - 2010. -
Ricardi U., Badellino S., Filippi A.R. Stereotactic radiotherapy for early stage non-small cell lung cancer // Radiat. Oncol. J. - 2015. - Vol. 33(2). - P. 57-65.
Roesch J., Panje C. Sterzing F., Mantel F., Nestle U. Andratschke N., Guckenberger M. СТЛТ for centrally localized NSCLC - What is too central? // Radiat. Oncol. - 2016. - Vol. 11. - P. 157-165.
Senthi S., Lagerwaard F.G., Haasbeek C.J.A., Slotman B.J., Senan S. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis // Lancet Oncol. - 2012. - Vol. 13. - P. 802-809.
Snee M.P, McParland L., Collinson F. et al. The SABRTooth feasibility trial protocol: a study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I non-small cell lung cancer (NSCLC) considered to be at higher risk of complications from surgical resection // Pilot and Feasibility Studies. - 2016. - Vol. 2. - P. 5. - 10.1186/s40814-016-0046 2 DOI: 10.1186/s40814-016-00462
Singh A.K., Suescun J.A.G., Stephans K.L. A Phase 2 Randomized Study of 2 Stereotactic Body Radiation Therapy Regimens for Medically Inoperable Patients With Node-Negative, Peripheral Non- Small Cell Lung Cancer // Int. J. Radiat. Oncol. Biol. Phys. - 2017. - 98. - P 221-222.
Shirvani S.M., Jiang J., Chang J.Y et al. Lobectomy, Sublobar Resection, and Stereotactic Radiation for Early-Stage Non-Small Cell Lung Cancers in the Elderly // JAMA Surg. - 2014. - Vol. 149(12). - P. 1244-1253.
Stahl J.M., Ross R., Harder E.M. et al. The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy // Int. J. Radiat. Oncol. Biol. Phys. - 2016. - Vol. 96. - P 1011-1020.
Sun B., Brooks E.D., Komaki R.U. et al. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung Cancer: Results of a phase 2 clinical trial // Cancer. - 2017. - Vol. 123(16). - Р. 3031-3039.
Timmerman R., Paulus R., Galvin J. et al. Stereotactic body radiation therapy for inoperable early stage lung cancer // JAMA. - 2010. - Vol. 303. - № 11. - P. 1070-1076.
Uzel E.K., Abacioglu U. Treatment of Early Stage Non-Small Cell Lung Cancer: Surgery or Stereotactic Ablative Radiotherapy? // Balkan Med. J.- 2015. - Vol. 32(1). -P. 8-16.
Yerokun B.A., Yang C.J., Gulack B.C. et al. A national analysis of wedge resection versus stereotactic body radiation therapy for stage IA non-small cell lung cancer // J. Thorac. Cardiovasc. Surg. - 2017. - Vol. 154(2). -P. 675-686.
Weickhardt A.J., Scheier B., Burke J.M. et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene addicted non-small cell lung cancer // J. Thorac. Oncol. -2012. - Vol. 7(12). - Р 1807-1814.
White A., Swanson S.J. Surgery versus stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer: less is not more // J. Thorac. Dis. - 2016. - Vol. 8(4). - P. 399-405.
Zhang J., Yang F., Li B. et al. Which is the optimal biologically effective dose of stereotactic body radiotherapy for Stage I non-small-cell lung cancer? A meta-analysis // Int. J. Radiat. Oncol. Biol. Phys. - 2011. - Vol. 81. -№ 4. - P. 305-316.
Zhang J., Kong L., Jiao Q., Li M., Yu J. Stereotactic ablative radiotherapy in treatment of early-stage non-small cell lung cancer: Unsolved questions and frontiers ahead // Cancer Lett. - 2017. - Vol. 401. - P. 46-52.
Zheng X., Schipper M., Kidwell K. et al. Survival outcome after stereotactic body radiation therapy and surgery for stage I non-small cell lung cancer: a meta-analysis // Int. J. Radiat. Oncol. Biol. Phys. - 2014. - Vol. 90. - № 3. - P 603-611.
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-NoDerivatives» («Атрибуция — Некоммерческое использование — Без производных произведений») 4.0 Всемирная.
© АННМО «Вопросы онкологии», Copyright (c) 2018